# Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

> **NCT00903110** · — · RECRUITING · sponsor: **Esteve Pharmaceuticals, S.A.** · enrollment: 500 (estimated)

## Conditions studied

- IGF1 Deficiency

## Interventions

- **DRUG:** Increlex®

## Key facts

- **NCT ID:** NCT00903110
- **Lead sponsor:** Esteve Pharmaceuticals, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2008-12-09
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00903110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00903110, "Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00903110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*